The National Institutes of Health National Center for Advancing Translational Sciences awarded multiple indefinite delivery contracts to support its drug development programs. The IDVs have a potential value of $19.4 million and a period of performance through June 2027. CCS Associates, Inc. received task orders against its IDV to provide regulatory support services. A $115,581 order involves preparing a Pre-Investigational New Drug Application for clinical development of mitragynine. A $242,355...
This federal contract IDV was awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services, to the prime contractor Kelly Services, Inc. The IDV has a ceiling value of $747,519,575 and an ultimate completion date of July 13, 2021. The contract provides for SCIENTIFIC, TECHNICAL, AND OTHER PROFESSIONAL SUPPORT SERVICES (STOPS) to NIDA, supporting the agency's biomedical research and public...
This Indefinite Delivery Contract (IDC) was awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the U.S. federal government, to In Vitro Strategies Limited Liability Company, a woman-owned small business. The contract has a total ceiling value of $187,438.64 and was set aside for small businesses. The purpose of this IDC is to provide in-vitro research and related services to support NIDA's mission. While the full scope of contracted work is not detailed, the...
This Indefinite Delivery Contract (IDC) is a single-award contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Sri International, a non-profit research and development organization. The contract, valued at a ceiling of $342,897, is for the provision of IN VITRO METABOLISM AND NON-CLINICAL ADME STUDIES over a 5-year period of performance from September 27, 2021 to April 25, 2025. The contract was not set aside for any specific business size or socioeconomic...
The Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse (NIDA) awarded an Indefinite Delivery Contract (IDC) to The Bizzell Group LLC, a U.S. Small Business Administration (SBA) certified HUBZone and minority-owned firm. The contract, valued at up to $1,000,000, provides logistics, communications, and clinical study auxiliary support services to NIDA's Division of Therapeutics and Medical Consequences from May 2021 through April 2026. To...
The federal contract IDV award is a single-award Indefinite Delivery Contract (IDC) with Johns Hopkins Bayview Medical Center, Inc. for the provision of clinical services in support of the National Institute on Drug Abuse (NIDA) Intramural Research Program (IRP). The contract, valued at a ceiling of $12,703,617.23, was awarded on January 15, 2008 by the Department of Health and Human Services (HHS) to the Johns Hopkins Bayview Medical Center, Inc. division of the Johns Hopkins Health System...
This indefinite delivery contract (IDC) was awarded by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services, to the prime contractor Caspian Sea, LLC, a minority-owned small business. The $1 million, single-award IDC has a performance period from 2019 to 2024 and is focused on providing professional and scientific support services to NIDA's Office of Extramural Policy and Review. Under this IDC, Caspian Sea has received multiple firm...
The National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), has awarded an indefinite delivery/indefinite quantity (IDIQ) contract to The Emmes Company LLC, a for-profit limited liability company, to serve as the NIDA Data, Statistics, and Clinical Trial Support Center. Under this single-award IDIQ contract valued up to $31.2 million over a five-year period from September 2022 to September 2027, The...
This federal contract indefinite delivery vehicle (IDV) award from the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) is a single-award contract with Eurofins Panlabs, Inc., a foreign-owned for-profit contract research organization. The $5 million, 5-year IDV is for receptor binding and predictive toxicology services to support the agency's drug abuse research programs. Under this IDV, two delivery orders have been issued to...
This Indefinite Delivery Contract (IDC) was awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the U.S. Department of Health and Human Services, to Technical Resources International, Inc. (TRI), a minority-owned, woman-owned, and Hispanic American-owned small business based in Bethesda, Maryland. The contract, valued at a ceiling of $2,500,000, is for the Pharmacokinetic Analysis Resource Center, which will provide support to clinical pharmacology and...
This federal contract IDV award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) provides regulatory affairs support services from CCS Associates, Inc., a Woman-Owned Small Business. The $2.4M single-award IDV covers a 5-year period from September 2023 to September 2028. Under the IDV, two delivery orders have been issued to date:
The first is a 1-year, $113,077 cost-plus-fixed-fee task order for regulatory affairs assistance to support NIDA's research and drug development initiatives. The second is a 1-year, $120,673 task order for continued regulatory affairs support. CCS Associates will leverage its expertise in areas like Investigational New Drug Applications, drug dossier development, and clinical trial coordination to aid NIDA. This IDV was originally solicited as a small business set-aside, aiming to identify qualified firms to provide a full-service Phase I clinical trials facility for the NIH's neurological disorder research programs.